Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia

    July 2026 in “ Figshare
    Yan Zhang (8098), Wenqiang Zhang (470965), Fen Tang, Liancheng Huang (22296339), Zhuolin Chen (12440679), Siqi Zhao (3164940), Rui Sun (177521), Xinhao Zhang (1306662), Xiaoling Shen (8782364), Yuanbin Hao (24361126), Tao Lu (39406), Shaofei Xie (2443456), Yadong Chen, Yu Jiao
    New to Pyrilutamide? There is a guide in the encyclopedia. Read the guide →
    Image

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →